Does Affinity Health Plan Cover Tirzepatide (Mounjaro)?

What Is Tirzepatide and Why Does the Diagnosis on File Matter So Much?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it under the brand name Mounjaro for type 2 diabetes in May 2022 [1]. A separate formulation, Zepbound, received FDA approval in November 2023 specifically for chronic weight management in adults with a body mass index of 30 or higher, or BMI <27 with at least one weight-related comorbidity [2].

This distinction matters enormously for insurance purposes. Payers, including Affinity Health Plan, generally apply different coverage rules depending on the diagnosis driving the prescription. A claim submitted with an ICD-10 code of E11.9 (type 2 diabetes) travels down one adjudication pathway. The same drug submitted under E66.01 (morbid obesity) travels down another, and Medicaid plans in New York, where Affinity primarily operates, have historically been more restrictive on obesity pharmacotherapy than on diabetes pharmacotherapy [3].

SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% on placebo (P<0.001) [4]. SURPASS-2 (N=1,879) showed that tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg at 40 weeks [5]. These trial results support broad clinical use, but clinical evidence and formulary coverage are separate questions entirely.

The 2023 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as preferred add-on therapy when additional glucose lowering is needed after metformin, particularly in patients with established cardiovascular disease or high cardiovascular risk [6]. Having that guideline language in a prior authorization letter substantially strengthens the case for approval.

How Affinity Health Plan Formularies Are Structured

Affinity Health Plan operates primarily as a Medicaid managed care organization and Essential Plan administrator in New York State, with a smaller commercial book. Each product line maintains a separate formulary, and tirzepatide's tier placement and coverage criteria differ across those products.

On most Medicaid managed care formularies administered by plans like Affinity, GLP-1 and dual GIP/GLP-1 agonists are placed on a specialty or non-preferred specialty tier, which is typically Tier 4 or Tier 5 [7]. Non-preferred placement means higher cost-sharing for the member and stricter clinical criteria for prior authorization approval. The New York State Medicaid Drug Utilization Review Board periodically reviews preferred drug list placements, and tirzepatide's position has shifted since its 2022 launch [8].

For the Essential Plan (a state-subsidized product for adults between 138% and 200% of the federal poverty level), cost-sharing is capped by statute, but prior authorization requirements still apply. Members on Medicaid have $0 copayments for covered drugs, making the prior authorization gate the primary barrier to access rather than out-of-pocket cost.

On commercial plans, the calculus changes. Tirzepatide may appear on a preferred specialty tier with a co-insurance of 20% to 30% after deductible, or on a non-preferred tier requiring co-insurance of 40% to 50%. The Eli Lilly savings program caps commercial patient costs at $25 per month for Mounjaro when the member has commercial insurance (not Medicaid or Medicare), though terms are subject to periodic revision [9].

Prior Authorization Requirements: What Affinity Typically Demands

Prior authorization for tirzepatide through Affinity follows a structured clinical review. The specific criteria below represent the standard framework applied by New York Medicaid managed care plans; individual requirements should always be confirmed with Affinity directly, as criteria are updated periodically.

Diagnosis documentation. The prescribing clinician must confirm a diagnosis of type 2 diabetes (E11.x) with a recent HbA1c result. Most plans require an HbA1c of 7.0% or higher to justify intensification of therapy, consistent with ADA guidelines recommending pharmacologic intervention when glycemic targets are not met within 3 months of lifestyle modification [6].

Step therapy. Metformin is the required first-line agent per virtually every payer guideline and per ADA standards [6]. Affinity and similar Medicaid plans typically require documented use of metformin at maximum tolerated dose for at least 3 months, plus trial and failure of at least one additional oral agent (commonly a sulfonylurea or SGLT-2 inhibitor), before a GLP-1 or dual agonist is approved [10]. If metformin is contraindicated (e.g., eGFR <30 mL/min/1.73m² or documented intolerance), that contraindication must be explicitly stated.

Cardiovascular or renal indication. Patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease may qualify for preferential access based on the 2023 ADA cardiovascular guidance, which states: "For patients with T2D and established CVD, a GLP-1 RA with proven CVD benefit is recommended" [6]. Including that language, plus the relevant ICD-10 codes (I25.10 for ASCVD, N18.x for CKD), can support medical necessity more effectively than diabetes metrics alone.

Weight management (Zepbound). If the prescription is for Zepbound rather than Mounjaro, additional criteria apply. The FDA label requires BMI of 30 or higher, or BMI <27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease) [2]. New York State Medicaid began covering anti-obesity medications more broadly starting in 2023 following a state budget provision, but managed care plans were given transition time to operationalize coverage, so actual approval rates vary [11].

Step-by-Step Prior Authorization Submission Process

Getting prior authorization approved requires coordination between the prescriber's office and the pharmacy. Here is the sequence that minimizes delays.

Step 1: Confirm the correct form. Affinity Health Plan uses a specific prior authorization request form for specialty medications. As of 2024, requests can be submitted through the Affinity provider portal, by fax to the specialty pharmacy benefit management team, or through the prescriber's electronic health record if integrated. Using an outdated form is one of the most common reasons for administrative denials [12].

Step 2: Attach clinical documentation upfront. The PA package should include the most recent HbA1c (dated within 6 months), current medication list showing step therapy attempts, relevant comorbidity diagnoses, and the prescriber's clinical justification letter. The ADA recommends A1C testing at least twice yearly in patients meeting glycemic targets and quarterly in those not meeting targets [6], so recent labs should be readily available.

Step 3: Use the correct NDC and drug name. Mounjaro (tirzepatide) and Zepbound (tirzepatide) are the same molecule but carry different NDC numbers and different indication labels. Submitting the wrong product for the diagnosis on file is a common technical denial cause [9].

Step 4: Request expedited review when clinically indicated. Federal Medicaid managed care rules require plans to render a standard PA decision within 14 calendar days and an expedited decision within 72 hours when the standard timeline could seriously jeopardize the member's health [13]. Document why expedited review is warranted if applicable (e.g., HbA1c above 10%, recent hospitalization for hyperglycemia).

Step 5: Track the request. The provider portal or a direct call to Affinity's pharmacy prior authorization line allows tracking. If no decision arrives within the regulatory timeframe, that itself constitutes grounds for an expedited appeal.

What to Do After a Denial

Denials fall into two categories: administrative (missing information, wrong form, incorrect NDC) and clinical (criteria not met). Each requires a different response.

Administrative denials can often be resolved by resubmitting with the correct documentation within 24 to 48 hours. No formal appeal is needed; the corrected submission restarts the review clock.

Clinical denials require a formal appeal. Under New York State regulations and CMS Medicaid managed care rules, members and providers have the right to a first-level internal appeal, followed by an external appeal conducted by an independent organization [13]. The external appeal process for Medicaid managed care in New York is administered through the New York State Department of Health. The standard external appeal decision timeline is 30 days, with 72 hours available for urgent cases [14].

For clinical appeals, the prescriber's letter should directly address the plan's stated denial reason and cite guideline support. The 2023 ADA Standards of Care statement on GLP-1 agonists in patients with cardiovascular risk [6] and the SURMOUNT-1 efficacy data showing 20.9% mean weight reduction at 72 weeks [4] are both appropriate citations for a Zepbound appeal. For a Mounjaro diabetes appeal, SURPASS-2 data showing HbA1c reduction of 2.46 percentage points [5] and FDA labeling language are relevant [1].

The American Diabetes Association's position statement on insulin and non-insulin injectables notes that cost and access barriers to GLP-1 therapy result in clinically meaningful delays in care for patients with type 2 diabetes and cardiovascular risk [15]. Including a reference to that position in an appeal letter signals clinical familiarity that can influence a medical director review.

Cost and Financial Assistance Options

Even with insurance, tirzepatide is expensive. The current list price for Mounjaro is approximately $1,069 for a 4-week supply. For Zepbound, the list price is approximately $1,060 for a comparable supply [9].

Eli Lilly savings programs. The Lilly Mounjaro Savings Card and the Zepbound Savings Card are available to commercially insured patients who are not enrolled in a federal or state government program. Eligible patients may pay as little as $25 per month. The program is not available to Medicaid or Medicare beneficiaries [9]. Income and other eligibility criteria apply, and the program terms can change without notice, so verifying directly at LillyDirect or the Lilly Cares Foundation site is recommended.

Lilly Cares Foundation. Uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level) may qualify for free or reduced-cost medication through the Lilly Cares patient assistance program [9]. Applications require prescriber participation and income documentation.

New York State Medicaid. For Affinity Medicaid members who obtain approval, the drug is covered at $0 copayment. The barrier is authorization, not cost-sharing. Pursuing the PA and appeal process fully is worth the effort for this population specifically because the financial benefit of approval is maximal.

Compounded tirzepatide. The FDA has issued guidance that tirzepatide is not currently on the drug shortage list as of early 2025, which restricts compounding pharmacy production of tirzepatide copies under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [16]. Patients considering compounded tirzepatide should understand that these products are not FDA-approved and that insurance, including Affinity, will not cover them. Safety risks associated with compounded GLP-1 products have been flagged in multiple FDA communications [16].

Clinical Efficacy Data Supporting Medical Necessity Arguments

When building a PA or appeal, having trial-specific numbers strengthens the case. These are the most relevant data points.

SURMOUNT-1 (N=2,539) showed tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 15.0%, 19.5%, and 20.9% respectively at 72 weeks, all versus 3.1% on placebo (P<0.001 for all doses) [4]. At the 15 mg dose, 57.8% of participants achieved at least 20% weight reduction. These figures exceed outcomes seen with any previously approved obesity pharmacotherapy.

SURPASS-2 (N=1,879) compared tirzepatide against semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide, a difference of 0.60 percentage points (P<0.001) [5]. Body weight decreased by 12.4 kg on tirzepatide 15 mg versus 6.2 kg on semaglutide 1 mg.

SURPASS-CVOT, a cardiovascular outcomes trial for tirzepatide, is ongoing [17]. Until those results are published, payers may reference the established cardiovascular benefit data for semaglutide from LEADER (N=9,340 to 13% relative risk reduction in major adverse cardiovascular events) and SUSTAIN-6 as class-level context for GLP-1 and dual agonist therapy [18]. Prescribers can cite these when arguing that delay in GLP-1 therapy access carries cardiovascular risk.

The FDA-approved Mounjaro prescribing information states that tirzepatide has not been studied in patients with a history of pancreatitis and should be used with caution in this population [1]. Including this in PA letters alongside contraindication language for alternative agents (e.g., why an SGLT-2 inhibitor is contraindicated in a specific patient) is a practical way to justify why tirzepatide is the appropriate next step rather than an alternative medication.

What Affinity Members Should Ask Their Prescriber Right Now

Patients who want tirzepatide covered through Affinity should come to their appointment prepared with specific information. The following checklist reflects best practice based on current ADA standards [6] and standard prior authorization workflows [12].

Bring documentation of any prior diabetes medications tried, including the approximate duration of use and the reason for stopping or switching. If metformin caused GI intolerance or is contraindicated due to renal function, have a recent comprehensive metabolic panel available to confirm eGFR. Bring blood pressure logs or a recent cardiovascular history summary if ASCVD, heart failure, or CKD applies. Know your most recent HbA1c number and the date it was drawn.

Ask the prescriber specifically whether the PA will be submitted for Mounjaro (diabetes indication) or Zepbound (weight management indication), because the supporting documentation requirements differ. Ask whether the practice uses an electronic PA submission platform integrated with Affinity, since electronic submission reduces administrative denial rates compared to fax-based submission [12].

If the prescriber's office is unfamiliar with Affinity's specific PA form or criteria, the Affinity provider services line and the pharmacy benefit manager (PBM) contracted by Affinity can both provide current criteria documents. Requesting those directly and bringing them to the prescriber before the appointment can save multiple weeks of back-and-forth.

The 2023 Obesity Medicine Association position statement notes that "obesity is a chronic, relapsing disease requiring long-term pharmacotherapy in many patients," supporting the medical necessity framework for extended tirzepatide coverage rather than a short-term trial authorization [19].

Monitoring and Dose Titration After Approval

Approval is not the end of the process. Affinity prior authorizations for specialty medications are typically granted for 12 months, after which a renewal PA is required. Renewal criteria generally include documented response to therapy, which for diabetes means A1C improvement from baseline, and for weight management means at least a 5% reduction in body weight at 12 weeks (the threshold below which the FDA label for Zepbound recommends reassessing therapy) [2].

The standard tirzepatide titration schedule starts at 2.5 mg weekly for 4 weeks, then increases by 2.5 mg every 4 weeks to a target dose of 5 mg to 15 mg weekly as tolerated [1]. Gastrointestinal side effects (nausea, vomiting, diarrhea) are most common during the first 8 to 12 weeks and are typically managed by slowing the titration schedule rather than discontinuing the drug [4]. Prescribers who document titration decisions and side effect management in the chart have stronger renewal PA submissions because they demonstrate active clinical management.

For renewal, submit updated HbA1c results (diabetes indication) or weight measurements with percentage change from baseline (obesity indication) at least 30 days before the current authorization expires to avoid a coverage gap. A gap in specialty medication coverage can trigger a step-down requirement in some plans, meaning the member must restart step therapy to requalify.